MA-FORRESTER
5.2.2024 15:01:26 CET | Business Wire | Press release
Forrester (Nasdaq: FORR) today opened calls for nominations for its 2024 global Technology Awards in two categories: Technology Strategy Impact and Enterprise Architecture. These awards recognize organizations that align their technology strategies to their business goals, are quick to adapt to changing market conditions, and focus on building customer trust. Strong alignment is critical to business results: According to Forrester, firms with strong alignment grow 2.4 times faster than peers and have twice the profitability.
Nomination criteria for Forrester’s Technology Awards are as follows:
- Technology Strategy Impact. Award recipients must execute a high-performance IT strategy, which Forrester defines as the pursuit of continuous improvement of business results through technology. Recipients must also demonstrate how they use alignment, trust, and adaptivity to enhance business outcomes with their IT capabilities.
- Enterprise Architecture. This award, presented in partnership with The Open Group — author of the TOGAF® standard, developed by The Open Group Architecture Forum — recognizes organizations that demonstrate how their outcome-driven enterprise architecture (EA) practice fuels change, growth, and differentiation. Organizations must also show how their EA practice helps their firm manage risk, drive cost efficiency, improve customer experience, and increase revenue.
Nominations for both award categories are open to organizations with 1,000 or more employees that are using technology to improve business outcomes. Technology leaders — including chief information officers, chief technology officers, chief digital officers, and enterprise architects across North America; Europe, the Middle East, and Africa (EMEA); and Asia Pacific (APAC) — are encouraged to apply.
Additional details on how to apply for Forrester’s 2024 Technology Awards:
- North America. Organizations in North America can visit here, with an awards submission deadline of May 20, 2024. Award recipients will be announced prior to and honored at Forrester’s Technology & Innovation Summit North America, being held in Austin, Texas, and digitally, September 9–12, 2024.
- EMEA. Organizations in EMEA can visit here, with an awards submission deadline of June 20, 2024. Award recipients will be announced prior to and honored at Forrester’s Technology & Innovation Summit EMEA, being held in London and digitally, October 9–11, 2024.
- Asia Pacific. Organizations in APAC can visit here, with an awards submission deadline of July 9, 2024. Award recipients will be announced prior to and honored at Forrester’s Technology & Innovation Summit APAC, being held in Sydney and digitally, October 29, 2024.
“Forrester’s Technology Awards will honor organizations that continually pursue the improvement of business results through technology,” said Laura Koetzle, vice president and group research director at Forrester. “These organizations embody the three guiding principles of high-performance IT strategy: alignment, trust, and adaptivity.”
“Enterprise architecture plays a critical role in driving growth and making a tangible difference in business outcomes. By identifying and describing the future and current state of the enterprise, EA provides one of the most effective ways to realize the organization’s objectives. Recognizing and celebrating EA practices and initiatives around the world has never been more important,” said Steve Nunn, president and CEO of The Open Group.
Resources:
- Learn more about Forrester’s 2024 Technology Awards program.
- Register to attend Forrester’s Technology & Innovation Summits 2024 in North America, EMEA, and APAC.
About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting, and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at the center of their leadership, strategy, and operations. Our unique insights are grounded in annual surveys of more than 700,000 consumers, business leaders, and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave™ evaluations; more than 100 million real-time feedback votes; and the shared wisdom of our clients. To learn more, visit Forrester.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240205913561/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom